Diseases / Anemia
Anemia
DiseaseAnemia is a condition in which the blood has a reduced number of red blood cells or hemoglobin, leading to decreased oxygen-carrying capacity and symptoms such as fatigue and weakness.
- Trials
- 1661
- Recruiting
- 103
- Completed
- 1065
- With results
- 341
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Available | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 1 | — | — | — | 6 | — | 1 | — | — | — | — | 8 |
| Phase 1 | 7 | — | — | — | 64 | 8 | 4 | — | 2 | — | — | 85 |
| Phase 1/2 | 6 | 1 | — | 2 | 14 | 10 | — | — | 4 | — | — | 37 |
| Phase 2 | 14 | 6 | — | 5 | 156 | 43 | 12 | — | 19 | — | — | 255 |
| Phase 2/3 | 1 | — | — | 3 | 13 | 1 | 1 | — | 3 | — | — | 22 |
| Phase 3 | 15 | 6 | — | 15 | 248 | 32 | 10 | 1 | 22 | — | — | 349 |
| Phase 4 | 12 | 11 | — | 2 | 116 | 26 | 2 | — | 27 | — | — | 196 |
| Not applicable | 20 | 15 | 3 | 9 | 243 | 18 | 18 | 1 | 44 | — | — | 371 |
| Unknown | 27 | 14 | 6 | 9 | 205 | 13 | 5 | — | 54 | 1 | 4 | 338 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Anemia | 8 | 85 | 37 | 255 | 22 | 349 | 196 | 371 | 338 | 1661 |
| Renal Insufficiency, Chronic | 2 | 12 | — | 48 | — | 69 | 28 | 11 | 17 | 187 |
| Anemia, Iron-Deficiency | 2 | 5 | 3 | 6 | 2 | 24 | 24 | 45 | 27 | 138 |
| Iron Deficiencies | 2 | 3 | 2 | 3 | 2 | 19 | 19 | 44 | 22 | 116 |
| Kidney Failure, Chronic | — | 4 | 2 | 25 | — | 18 | 18 | 5 | 8 | 80 |
| Neoplasms | — | 2 | 2 | 21 | 1 | 19 | 9 | 5 | 14 | 73 |
| Myelodysplastic Syndromes | — | 7 | 4 | 27 | 2 | 17 | 1 | 2 | 9 | 69 |
| Malaria | — | — | — | 1 | — | 10 | 11 | 31 | 9 | 62 |
| Hematologic Diseases | — | 7 | 2 | 12 | — | 9 | 2 | 5 | 11 | 48 |
| Anemia, Sickle Cell | — | 3 | 6 | 13 | — | 3 | 1 | 8 | 7 | 41 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Hoffmann-La Roche | 96 | 43 |
| 2 | Amgen | 62 | 27 |
| 3 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 58 | 21 |
| 4 | GlaxoSmithKline | 34 | 9 |
| 5 | London School of Hygiene and Tropical Medicine | 27 | 7 |
| 6 | Akebia Therapeutics | 21 | 9 |
| 7 | American Regent, Inc. | 18 | 15 |
| 8 | Kyntra Bio | 18 | 9 |
| 9 | Affymax | 13 | 4 |
| 10 | Bayer | 13 | 5 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Epoetin Alfa | 162 |
| 2 | Darbepoetin alfa | 117 |
| 3 | continuous erythropoietin receptor activator | 68 |
| 4 | Iron | 63 |
| 5 | ferric carboxymaltose | 61 |
| 6 | ferrous sulfate | 53 |
| 7 | epoetin beta | 41 |
| 8 | Ferric Oxide, Saccharated | 38 |
| 9 | roxadustat | 34 |
| 10 | Iron-Dextran Complex | 33 |
Evidence
- Results reported
- 32%341 of 1065 completed
- Published
- 17%181 of 1065 completed
- Primary endpoint met
- 42.9%93 of 217 analyses
- Median months to report
- 27
Documents disclosed
Trial profile
- Median enrollment
- 128
- Median duration
- 24months
- Countries
- 118
- Study sites
- 12798
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 56
- Phase 1
- 30
- Phase 1/2
- 35
- Phase 2
- 60
- Phase 2/3
- 138
- Phase 3
- 211
- Phase 4
- 129
- Not applicable
- 180
- Unknown
- 266
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Houston | United States | 107 |
| 2 | Los Angeles | United States | 95 |
| 3 | London | United Kingdom | 89 |
| 4 | New York | United States | 82 |
| 5 | Barcelona | Spain | 75 |
| 6 | Paris | France | 71 |
| 7 | Philadelphia | United States | 68 |
| 8 | San Antonio | United States | 66 |
| 9 | Madrid | Spain | 65 |
| 10 | Detroit | United States | 60 |
Terminations
- Terminated
- 151
- Withdrawn
- 53
- Suspended
- 2
- Stopped for recruitment
- 4.3%72 of 1661 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT06098755 Withdrawn | Withdrawn | No Participants Enrolled | 2028-12-31 |
| NCT07255846 Withdrawn | Withdrawn | This decision is based solely on internal company prioritization and resource allocation considerations. No patients have been enrolled or dosed in this study and no clinical data have been generated. | 2028-03-31 |
| NCT04921696 Withdrawn | Withdrawn | no patients were included | 2026-12-31 |
| NCT05082571 Withdrawn | Withdrawn | Sponsor decision | 2026-10-31 |
| NCT05082584 Withdrawn | Withdrawn | Sponsor decision | 2026-10-31 |
| NCT05457790 Suspended | Suspended | Study on hold pending consideration for amendment. | 2026-10-31 |
| NCT06508827 Withdrawn | Withdrawn | Difficulty recruiting participants | 2026-06-30 |
| NCT07025512 Withdrawn | Withdrawn | PI requested | 2026-05-04 |
| NCT03810911 Terminated | Terminated | The trial was stopped because of inability to reach target sample size. | 2025-07-31 |
| NCT04020224 Withdrawn | Withdrawn | Sponsor's decision | 2025-03-31 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: